Belhaven Biopharma Overview
- Year Founded
-
2020
- Status
-
Private
- Employees
-
3
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$32.3M
- Investors
-
1
Belhaven Biopharma General Information
Description
Developer of a life-saving medication designed for the treatment of anaphylaxis. The company is developing a portfolio of dry powder nasal medicines to provide convenient, safe, and rapid treatments in emergencies, enabling patients to get quick treatment.
Contact Information
Website
www.belhavenbio.comCorporate Office
- 150 Fayetteville Street
- Suite 2300
- Raleigh, NC 27601
- United States
Corporate Office
- 150 Fayetteville Street
- Suite 2300
- Raleigh, NC 27601
- United States
Belhaven Biopharma Timeline
Belhaven Biopharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Later Stage VC | 15-Oct-2025 | $32.3M | Completed | Clinical Trials - General | ||
| 6. Seed Round | 21-Jan-2025 | Completed | Clinical Trials - General | |||
| 5. Angel (individual) | 10-Jan-2024 | Completed | Clinical Trials - General | |||
| 4. Debt - General | 16-Feb-2023 | Completed | Product Development | |||
| 3. Angel (individual) | 03-Sep-2022 | Completed | Product Development | |||
| 2. Debt - General | 30-Jul-2021 | $250K | $1.64M | Completed | Product Development | |
| 1. Angel (individual) | 12-Feb-2021 | $1.39M | $1.39M | Completed | Startup |
Belhaven Biopharma Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A-5 | ||||||||
| Series A-4 | ||||||||
| Series A-3 | ||||||||
| Series A-2 | 1,007,001 | $0.001000 | $1.73 | $1.73 | 1x | $1.73 | 14.39% | |
| Series A-1 | 605,579 | $0.001000 | $19.82 | $19.82 | 1x | $19.82 | 8.65% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Belhaven Biopharma Comparisons
Industry
Financing
Details
Belhaven Biopharma Competitors (1)
One of Belhaven Biopharma’s competitors is ARS Pharmaceuticals, a Formerly VC-backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| ARS Pharmaceuticals | Formerly VC-backed | San Diego, CA |
Belhaven Biopharma Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Belhaven Biopharma Patents
Belhaven Biopharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-12502498-B1 | Compositions, devices, and methods for intranasal delivery of dry powder epinephrine | Active | 21-Oct-2024 | ||
| US-12605517-B1 | Compositions, devices, and methods for intranasal delivery of dry powder epinephrine | Active | 21-Oct-2024 | ||
| US-12653972-B2 | Compositions, devices, and methods for intranasal delivery of dry powder epinephrine | Active | 21-Oct-2024 | ||
| US-12678574-B2 | Compositions, devices, and methods for intranasal delivery of dry powder epinephrine | Active | 21-Oct-2024 | ||
| US-20260108459-A1 | Compositions, devices, and methods for intranasal delivery of dry powder epinephrine | Active | 21-Oct-2024 | A61M15/08 |
Belhaven Biopharma Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Belhaven Biopharma Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Xcendra Ventures | Venture Capital | Minority |
Belhaven Biopharma FAQs
-
When was Belhaven Biopharma founded?
Belhaven Biopharma was founded in 2020.
-
Where is Belhaven Biopharma headquartered?
Belhaven Biopharma is headquartered in Raleigh, NC.
-
What is the size of Belhaven Biopharma?
Belhaven Biopharma has 3 total employees.
-
What industry is Belhaven Biopharma in?
Belhaven Biopharma’s primary industry is Drug Discovery.
-
Is Belhaven Biopharma a private or public company?
Belhaven Biopharma is a Private company.
-
What is the current valuation of Belhaven Biopharma?
The current valuation of Belhaven Biopharma is .
-
What is Belhaven Biopharma’s current revenue?
The current revenue for Belhaven Biopharma is .
-
How much funding has Belhaven Biopharma raised over time?
Belhaven Biopharma has raised $51.2M.
-
Who are Belhaven Biopharma’s investors?
Xcendra Ventures has invested in Belhaven Biopharma.
-
Who are Belhaven Biopharma’s competitors?
ARS Pharmaceuticals is a competitor of Belhaven Biopharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
